237 related articles for article (PubMed ID: 28153094)
1. A Synthetic-Biology-Inspired Therapeutic Strategy for Targeting and Treating Hepatogenous Diabetes.
Xue S; Yin J; Shao J; Yu Y; Yang L; Wang Y; Xie M; Fussenegger M; Ye H
Mol Ther; 2017 Feb; 25(2):443-455. PubMed ID: 28153094
[TBL] [Abstract][Full Text] [Related]
2. An Inducible CRISPR-dCas9-Based Transcriptional Repression System for Cancer Therapy.
Gu P; Zhao J; Zhang W; Ruan X; Hu L; Zeng Y; Hou X; Zheng X; Gao M; Chi J
Small Methods; 2024 Jan; ():e2301310. PubMed ID: 38164884
[TBL] [Abstract][Full Text] [Related]
3. Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects.
Wang X; Liu R; Zhang W; Zhang X; Liao N; Wang Z; Li W; Qin X; Hai C
Mol Cell Endocrinol; 2013 Aug; 376(1-2):70-80. PubMed ID: 23791844
[TBL] [Abstract][Full Text] [Related]
4. Engineering Mammalian Designer Cells for the Treatment of Metabolic Diseases.
Wang Y; Wang M; Dong K; Ye H
Biotechnol J; 2018 May; 13(5):e1700160. PubMed ID: 29144600
[TBL] [Abstract][Full Text] [Related]
5. A synthetic optogenetic transcription device enhances blood-glucose homeostasis in mice.
Ye H; Daoud-El Baba M; Peng RW; Fussenegger M
Science; 2011 Jun; 332(6037):1565-8. PubMed ID: 21700876
[TBL] [Abstract][Full Text] [Related]
6. Treatment of diabetes with glucagon-like peptide-1 gene therapy.
Riedel MJ; Kieffer TJ
Expert Opin Biol Ther; 2010 Dec; 10(12):1681-92. PubMed ID: 21029027
[TBL] [Abstract][Full Text] [Related]
7. Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice.
Riedel MJ; Lee CW; Kieffer TJ
Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E936-44. PubMed ID: 19190262
[TBL] [Abstract][Full Text] [Related]
8. Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states.
Moreno P; Nuche-Berenguer B; Gutiérrez-Rojas I; Acitores A; Sancho V; Valverde I; González N; Villanueva-Peñacarrillo ML
J Mol Endocrinol; 2012 Feb; 48(1):37-47. PubMed ID: 22065862
[TBL] [Abstract][Full Text] [Related]
9. Modified human glucagon-like peptide-1 (GLP-1) produced in E. coli has a long-acting therapeutic effect in type 2 diabetic mice.
Xu F; Wang KY; Wang N; Li G; Liu D
PLoS One; 2017; 12(7):e0181939. PubMed ID: 28750064
[TBL] [Abstract][Full Text] [Related]
10. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.
Lee Y; Kwon MK; Kang ES; Park YM; Choi SH; Ahn CW; Kim KS; Park CW; Cha BS; Kim SW; Sung JK; Lee EJ; Lee HC
J Gene Med; 2008 Mar; 10(3):260-8. PubMed ID: 18085721
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 effect upon the GPI/IPG system in adipocytes and hepatocytes from diabetic rats.
Márquez L; González N; Puente J; Valverde L; Villanueva-Peñacarrillo ML
Diabetes Nutr Metab; 2001 Oct; 14(5):239-44. PubMed ID: 11806463
[TBL] [Abstract][Full Text] [Related]
12. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states.
Nuche-Berenguer B; Moreno P; Esbrit P; Dapía S; Caeiro JR; Cancelas J; Haro-Mora JJ; Villanueva-Peñacarrillo ML
Calcif Tissue Int; 2009 Jun; 84(6):453-61. PubMed ID: 19219381
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antihyperglycemic effects between plant-derived oleanolic acid and insulin in streptozotocin-induced diabetic rats.
Musabayane CT; Tufts MA; Mapanga RF
Ren Fail; 2010; 32(7):832-9. PubMed ID: 20662697
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice.
Kumar M; Hunag Y; Glinka Y; Prud'homme GJ; Wang Q
Gene Ther; 2007 Jan; 14(2):162-72. PubMed ID: 16943856
[TBL] [Abstract][Full Text] [Related]
15. Over-expression of the glucagon-like peptide-1 receptor on INS-1 cells confers autocrine stimulation of insulin gene promoter activity: a strategy for production of pancreatic beta-cell lines for use in transplantation.
Chepurny OG; Holz GG
Cell Tissue Res; 2002 Feb; 307(2):191-201. PubMed ID: 11845326
[TBL] [Abstract][Full Text] [Related]
16. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models.
Villanueva-Peñacarrillo ML; Puente J; Redondo A; Clemente F; Valverde I
Endocrine; 2001 Jul; 15(2):241-8. PubMed ID: 11720253
[TBL] [Abstract][Full Text] [Related]
17. The role of dysregulated glucagon secretion in type 2 diabetes.
D'Alessio D
Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():126-32. PubMed ID: 21824266
[TBL] [Abstract][Full Text] [Related]
18. GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.
Tomas E; Wood JA; Stanojevic V; Habener JF
Regul Pept; 2011 Aug; 169(1-3):43-8. PubMed ID: 21549160
[TBL] [Abstract][Full Text] [Related]
19. Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes.
Wick A; Newlin K
J Am Acad Nurse Pract; 2009 Nov; 21 Suppl 1():623-30. PubMed ID: 19900193
[TBL] [Abstract][Full Text] [Related]
20. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
Baron AD; Kim D; Weyer C
Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
